基本説明
Special Issue: Neurodegenerative Diseases 2005, Vol. 2, No. 3-4.
Contents
Structure of SOD1 MutantsInstability: Implications for Toxicity in Amyotrophic Lateral Sclerosis: Tiwari, A.; Hayward, L.J.; Molecular Signaling in ALS; Inter- and Intracellular Signaling in Amyotrophic Lateral Sclerosis: Role of p38 Mitogen-Activated Protein Kinase: Bendotti, C. et al.; Anti-ALS Activity of Alsin, the Product of the ALS2 Gene, and Activity-Dependent Neurotrophic Factor: Matsuoka, M.; Nishimoto, I.; Toxicity Pathways in ALS Complexity of Astrocyte-Motor Neuron Interactions in Amyotrophic Lateral Sclerosis: Pehar, M. et al.; Excitotoxicity and Amyotrophic Lateral Sclerosis: Van Damme, P.; Dewil, M.; Robberecht, W.; Van Den Bosch, L.; Enprofylline Protects Motor Neurons from in vitro Excitotoxic Challenge: Mojsilovic-Petrovic, J.; Arneja, A.; Kalb R.G.; Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis: Guillemin, G.J.; Meininger, V.; Brew, B.J.; Diagnostic Markers of ALS; Amyotrophic Lateral Sclerosis: New Developments in Diagnostic Markers: Dengler, R.; von Neuhoff, N.; Bufler, J.; Krampfl, K.; Peschel, T.; Grosskreutz, J.; Reticulons as Markers of Neurological Diseases: Focus on Amyotrophic Lateral Sclerosis: Fergani, A. et al.; Clinical and Epidemiological Aspects of ALS; Lead Exposure as a Risk Factor for Amyotrophic Lateral Sclerosis: Kamel, F. et al.; Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters: Desport, J.-C.; Torny, F.; Lacoste, M.; Preux, P.-M.; Couratier, P.; Clinical Trials in ALS: What Did We Learn from Recent Trials in Humans? Meininger, V.; Therapeutic Strategies; Preclinical Trials - An Update on Translational Research in ALS: Ludolph, A.C.; Sperfeld, A.-D.; Promises and Challenges in Developing RNAi as a Research Tool and Therapy for Neurodegenerative Diseases: Xia, X.G.; Zhou, H.; Xu, Z..
